BR112013015010A2 - produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana - Google Patents
produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbianaInfo
- Publication number
- BR112013015010A2 BR112013015010A2 BR112013015010A BR112013015010A BR112013015010A2 BR 112013015010 A2 BR112013015010 A2 BR 112013015010A2 BR 112013015010 A BR112013015010 A BR 112013015010A BR 112013015010 A BR112013015010 A BR 112013015010A BR 112013015010 A2 BR112013015010 A2 BR 112013015010A2
- Authority
- BR
- Brazil
- Prior art keywords
- product
- treating
- substrate
- pharmaceutical composition
- microbial infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122019015601-8A BR122019015601B1 (pt) | 2010-12-14 | 2011-12-14 | produto, substrato, composição farmacêutica e uso de um produto |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42300010P | 2010-12-14 | 2010-12-14 | |
| GBGB1021186.0A GB201021186D0 (en) | 2010-12-14 | 2010-12-14 | Composition |
| GB1021186.0 | 2010-12-14 | ||
| US61/423,000 | 2010-12-14 | ||
| PCT/GB2011/001721 WO2012080700A1 (en) | 2010-12-14 | 2011-12-14 | A composition comprising an antibiotic and a dispersant or an anti -adhesive agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013015010A2 true BR112013015010A2 (pt) | 2016-08-09 |
| BR112013015010B1 BR112013015010B1 (pt) | 2021-01-05 |
Family
ID=43567164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013015010-6A BR112013015010B1 (pt) | 2010-12-14 | 2011-12-14 | produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana |
| BR122019015601-8A BR122019015601B1 (pt) | 2010-12-14 | 2011-12-14 | produto, substrato, composição farmacêutica e uso de um produto |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122019015601-8A BR122019015601B1 (pt) | 2010-12-14 | 2011-12-14 | produto, substrato, composição farmacêutica e uso de um produto |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9782423B2 (pt) |
| EP (2) | EP2651419B1 (pt) |
| JP (2) | JP5964854B2 (pt) |
| KR (1) | KR101955636B1 (pt) |
| CN (1) | CN103732232B (pt) |
| AU (3) | AU2011343012C1 (pt) |
| BR (2) | BR112013015010B1 (pt) |
| CA (1) | CA2821032C (pt) |
| CY (2) | CY1117447T1 (pt) |
| DK (2) | DK2651419T3 (pt) |
| ES (2) | ES2565564T3 (pt) |
| GB (1) | GB201021186D0 (pt) |
| HK (2) | HK1185015A1 (pt) |
| HR (2) | HRP20160235T1 (pt) |
| HU (2) | HUE027207T2 (pt) |
| IL (2) | IL226879B (pt) |
| LT (1) | LT3040076T (pt) |
| MX (1) | MX346664B (pt) |
| NZ (1) | NZ613076A (pt) |
| PL (2) | PL2651419T3 (pt) |
| PT (1) | PT3040076T (pt) |
| RS (2) | RS61469B1 (pt) |
| RU (2) | RU2607660C2 (pt) |
| SG (3) | SG10201510095YA (pt) |
| SI (2) | SI3040076T1 (pt) |
| SM (1) | SMT201600121B (pt) |
| UA (1) | UA114470C2 (pt) |
| WO (1) | WO2012080700A1 (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101801521B (zh) | 2007-05-14 | 2015-06-17 | 纽约州立大学研究基金会 | 生物膜中细菌细胞内的生理学分散响应诱导 |
| GB0905451D0 (en) * | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| PT106094A (pt) | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | Administração por inalação de formulações com dose elevada |
| US20150273025A1 (en) * | 2012-09-28 | 2015-10-01 | The Regents Of The University Of Michigan | Apyrase treatments |
| GB201416727D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| GB201416716D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| US10617703B2 (en) | 2014-12-10 | 2020-04-14 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| GB201510077D0 (en) * | 2015-06-10 | 2015-07-22 | Novabiotics Ltd | Use |
| US11690815B2 (en) | 2015-08-05 | 2023-07-04 | Cmpd Licensing Llc | Hyperkeratotic skin condition treatments and compositions |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11278590B2 (en) | 2015-08-05 | 2022-03-22 | Cmpd Licensing, Llc | Compositions and methods for treating nail infections |
| US10898455B2 (en) | 2016-01-07 | 2021-01-26 | Cmpd Licensing, Llc | Urea cream formulations |
| US10898491B2 (en) | 2015-12-18 | 2021-01-26 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| GB2565511B (en) | 2016-05-26 | 2022-04-13 | Kimberly Clark Co | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| GB201609940D0 (en) * | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Microparticles |
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| WO2017212239A1 (en) * | 2016-06-07 | 2017-12-14 | Novabiotics Limited | Treatment of drug-resistant microbial infections |
| WO2018093364A1 (en) * | 2016-11-16 | 2018-05-24 | The Regents Of The University Of California | Formulations of cysteamine and cystamine |
| US11737975B2 (en) | 2016-11-17 | 2023-08-29 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10966946B2 (en) | 2016-11-17 | 2021-04-06 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
| CN110049761A (zh) * | 2016-12-15 | 2019-07-23 | 萨宝公司 | N-乙酰半胱氨酸作为抗菌剂的用途 |
| EP3366284A1 (en) * | 2017-02-27 | 2018-08-29 | Zambon S.p.A. | Association of n-acetylcysteine and colistin for use in bacterial infections |
| EP3592335A4 (en) | 2017-04-10 | 2021-01-27 | The University of North Carolina at Chapel Hill | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR INHIBITING A Pathogen and / or Modifying Slime |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| WO2020079186A1 (en) * | 2018-10-17 | 2020-04-23 | Novabiotics Limited | Dosage regime |
| US20220265583A1 (en) * | 2019-07-30 | 2022-08-25 | The Regents Of The University Of California | Methods and composition for treating respiratory obstructive diseases |
| CN111053696B (zh) * | 2019-11-19 | 2022-11-04 | 温州医科大学附属口腔医院 | 一种抑制细菌粘附的超疏水凝胶纳米涂层及制备方法 |
| CN113018443B (zh) * | 2019-12-27 | 2022-09-13 | 海南斯达制药有限公司 | 治疗呼吸系统疾病的药物组合物及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1055560B (it) | 1974-05-02 | 1982-01-11 | Istituto Chemioterapico | Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali |
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IT1178869B (it) | 1984-03-07 | 1987-09-16 | Cagliero Germano | Prodotto per prevenire e combattere le tossicosi alimentari dovute a micotossine |
| US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| EP0752885B1 (en) | 1992-09-25 | 2003-07-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5696164A (en) * | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| JP3749279B2 (ja) | 1995-03-01 | 2006-02-22 | 日産化学工業株式会社 | 爪用抗真菌剤 |
| US5624704A (en) * | 1995-04-24 | 1997-04-29 | Baylor College Of Medicine | Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent |
| US6086921A (en) | 1995-04-25 | 2000-07-11 | Wintrop-University Hospital | Metal/thiol biocides |
| US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| US6475434B1 (en) * | 1998-12-07 | 2002-11-05 | Baylor College Of Medicine | Composition and methods for preventing and removing biofilm embedded microorganisms from the surface of medical devices |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| ITMI20021881A1 (it) | 2002-09-04 | 2004-03-05 | Zambon Spa | Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario. |
| GB2398497A (en) | 2003-02-19 | 2004-08-25 | Walcom Animal Science | Composition for improving immunity of animals |
| AR047779A1 (es) | 2003-12-19 | 2006-02-22 | Omega Bio Pharma Ip3 Ltd | Composiciones y metodos para tratar diabetes |
| PT1778720E (pt) | 2004-08-18 | 2010-11-29 | Novabiotics Ltd | Péptidos antimicrobianos compreendendo um motivo com arginina e/ou lisina |
| US20070093894A1 (en) * | 2005-10-25 | 2007-04-26 | Baylor College Of Medicine | Incorporation of antimicrobial combinations onto devices to reduce infection |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| ZA200805191B (en) | 2005-11-28 | 2009-08-26 | Hk Omega Biopharma Ltd | Materials and methods for treating viral infections with a cysteamine compound |
| US20070172514A1 (en) * | 2006-01-20 | 2007-07-26 | Francis Chi | Materials and methods for improving livestock productivity |
| DE102006010642A1 (de) | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| US20080035141A1 (en) * | 2006-06-16 | 2008-02-14 | Warner W R | Aerosolized therapy kit |
| EP2099466B1 (en) * | 2006-12-01 | 2015-06-03 | Laclede, Inc. | Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears |
| US20080131500A1 (en) * | 2006-12-04 | 2008-06-05 | The Board Of Regents Of The University Of Texas System | Methods and compositions for rapid inactivation of proteins |
| WO2008092262A1 (en) | 2007-01-31 | 2008-08-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Methods and compounds for treatment, prevention and diagnosis of parasitic infection and disease |
| GB0702021D0 (en) | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| WO2008124706A2 (en) | 2007-04-06 | 2008-10-16 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Devices and methods for target molecule characterization |
| EP1994930A1 (en) * | 2007-05-22 | 2008-11-26 | Novartis AG | Triazol compounds for treating biofilm formation |
| RU2371447C2 (ru) * | 2007-10-05 | 2009-10-27 | Общество С Ограниченной Ответственностью "Саентифик Фьючер Менеджмент" | Конъюгат антибиотика и антибактериальное лекарственное средство на его основе |
| WO2009076722A1 (en) | 2007-12-19 | 2009-06-25 | The University Of Melbourne | Method of protecting a surface from biological fouling |
| BRPI0821985A2 (pt) * | 2008-01-10 | 2015-06-23 | Evonik Roehm Gmbh | Preparacao farmacêutica ou nutracêutica revestida tendo liberação de substância ativa controlada |
| CN102006785A (zh) | 2008-02-17 | 2011-04-06 | 华扩达动物科学(I.P.3)有限公司 | 改善虾健康的材料和方法 |
| CN102341105B (zh) * | 2009-02-03 | 2014-09-17 | 微生物公司 | 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇 |
| GB0905451D0 (en) | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| US8815942B2 (en) * | 2010-10-20 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| US20150071904A1 (en) | 2012-01-06 | 2015-03-12 | Trustees Of Boston University | Compositions and methods to boost endogenous ros production from bacteria |
| US20160106689A1 (en) | 2014-09-22 | 2016-04-21 | Novabiotics Limited | Use |
-
2010
- 2010-12-14 GB GBGB1021186.0A patent/GB201021186D0/en not_active Ceased
-
2011
- 2011-12-14 BR BR112013015010-6A patent/BR112013015010B1/pt active IP Right Grant
- 2011-12-14 KR KR1020137017966A patent/KR101955636B1/ko active IP Right Grant
- 2011-12-14 SI SI201131956T patent/SI3040076T1/sl unknown
- 2011-12-14 EP EP11808253.6A patent/EP2651419B1/en active Active
- 2011-12-14 SG SG10201510095YA patent/SG10201510095YA/en unknown
- 2011-12-14 LT LTEP15192845.4T patent/LT3040076T/lt unknown
- 2011-12-14 HU HUE11808253A patent/HUE027207T2/en unknown
- 2011-12-14 RU RU2013131391A patent/RU2607660C2/ru not_active IP Right Cessation
- 2011-12-14 RU RU2016151115A patent/RU2739249C2/ru active
- 2011-12-14 CN CN201180064011.0A patent/CN103732232B/zh active Active
- 2011-12-14 UA UAA201308670A patent/UA114470C2/uk unknown
- 2011-12-14 JP JP2013543872A patent/JP5964854B2/ja active Active
- 2011-12-14 ES ES11808253.6T patent/ES2565564T3/es active Active
- 2011-12-14 EP EP15192845.4A patent/EP3040076B1/en active Active
- 2011-12-14 PT PT151928454T patent/PT3040076T/pt unknown
- 2011-12-14 NZ NZ613076A patent/NZ613076A/en unknown
- 2011-12-14 WO PCT/GB2011/001721 patent/WO2012080700A1/en active Application Filing
- 2011-12-14 HU HUE15192845A patent/HUE053813T2/hu unknown
- 2011-12-14 SG SG2013045612A patent/SG191146A1/en unknown
- 2011-12-14 BR BR122019015601-8A patent/BR122019015601B1/pt active IP Right Grant
- 2011-12-14 DK DK11808253.6T patent/DK2651419T3/en active
- 2011-12-14 CA CA2821032A patent/CA2821032C/en active Active
- 2011-12-14 SI SI201130756A patent/SI2651419T1/sl unknown
- 2011-12-14 RS RS20210194A patent/RS61469B1/sr unknown
- 2011-12-14 MX MX2013006873A patent/MX346664B/es active IP Right Grant
- 2011-12-14 SM SM201600121T patent/SMT201600121B/it unknown
- 2011-12-14 PL PL11808253T patent/PL2651419T3/pl unknown
- 2011-12-14 DK DK15192845.4T patent/DK3040076T3/da active
- 2011-12-14 AU AU2011343012A patent/AU2011343012C1/en not_active Ceased
- 2011-12-14 RS RS20160173A patent/RS54815B1/sr unknown
- 2011-12-14 SG SG10201703290UA patent/SG10201703290UA/en unknown
- 2011-12-14 PL PL15192845T patent/PL3040076T3/pl unknown
- 2011-12-14 ES ES15192845T patent/ES2856831T3/es active Active
-
2012
- 2012-06-01 US US13/486,778 patent/US9782423B2/en active Active
-
2013
- 2013-06-11 IL IL226879A patent/IL226879B/en active IP Right Grant
- 2013-11-06 HK HK13112496.9A patent/HK1185015A1/zh not_active IP Right Cessation
-
2014
- 2014-08-15 US US14/460,953 patent/US9364491B2/en active Active
-
2016
- 2016-02-11 US US15/041,393 patent/US11020414B2/en active Active
- 2016-03-07 HR HRP20160235TT patent/HRP20160235T1/hr unknown
- 2016-03-18 CY CY20161100233T patent/CY1117447T1/el unknown
- 2016-06-30 JP JP2016129761A patent/JP6483058B2/ja active Active
- 2016-07-29 HK HK16109088.6A patent/HK1220911A1/zh unknown
-
2017
- 2017-03-10 AU AU2017201670A patent/AU2017201670B2/en active Active
-
2018
- 2018-12-17 AU AU2018282257A patent/AU2018282257A1/en not_active Abandoned
-
2020
- 2020-07-28 IL IL276342A patent/IL276342A/en unknown
-
2021
- 2021-02-17 CY CY20211100132T patent/CY1123951T1/el unknown
- 2021-02-18 HR HRP20210280TT patent/HRP20210280T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013015010A2 (pt) | produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BR112014003681A8 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
| BR112013011737A2 (pt) | composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112012029227A2 (pt) | processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto | |
| BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
| ES2968043T3 (es) | Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que comprende la misma | |
| BR112014008126A2 (pt) | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção | |
| BR112013001571A2 (pt) | composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40 | |
| BR112012015248A2 (pt) | composto composição farmacêutica,método para inibir ativi dades de ck1, método para inibir atividade de ck2 e uso de um composto ou uma composição farmacêutica | |
| BR112014010186A2 (pt) | formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal | |
| ES2898695T8 (es) | Derivados de benzoxaborol para el tratamiento de infecciones bacterianas | |
| BR112013010738A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção viral | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| BR112012026843A2 (pt) | composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv | |
| BR112012023355A2 (pt) | composto, composição farmacêutica e método de ruptura da interação nek2/hec1 | |
| BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16D | Grant of patent or certificate of addition of invention cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2595 DE 29/09/2020 POR TER SIDO INDEVIDA. |
|
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |